跳至主要内容
临床试验/JPRN-jRCTs021180022
JPRN-jRCTs021180022招募中2 期

A Phase 2 Trial of Multimodal Treatment based on VDC-IE with Interval Compressed Schedule by using G-CSF for Patients with Non-metastatic Ewing Sarcoma Family Tumor - JESS14

Sano Hideki0 个研究点目标入组 66 人开始时间: 2019年3月25日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 < 50age old(—)
性别
All

入选标准

  • 1. Histologically confirmed newly diagnosed ESFT.
  • 2. Localized tumor.
  • 3. Within 3 weeks after histologically diagnosis.
  • 4. No history of prior chemotherapy or radiation therapy.
  • 5. Age younger than 50 years old.
  • 6. Patients must have sufficient organ function satisfying the labolatory data
  • listed below.
  • 7. All patients and/or their parents or legal guardians must sign a written
  • informed consent.
  • 8. Remain evaluable lesion.(Not complete resection)
  • 9. Completion of primary registration for pediatric solid tumor database.

排除标准

  • 1. Patients with synchronous or metachronous concomitant malignancies.
  • 2. Patients who are pregnant or breast feeding mother.
  • 3. Patients with mental disorder who is considered inappropriate for study
  • participation.
  • 4. Patients with heart disease which required any therapy.
  • 5. Patients with active infection which required any therapy.
  • 6. Patients with any other inappropriate condition for study participation judged
  • by physician.
  • 7. HBs antigen positive. HBs antigen negative but HBc antibody or HBs
  • antibody positive. ( exclude HBs antibody positive due to HBV vaccination)
  • 8. Patients who had continuous steroid therapy.

研究者

发起方
Sano Hideki

相似试验

JESS14 | 临床试验